Expertise Built on the MENA Ground.
10+ years of activated networks. Regulatory files submitted to SFDA, MOH, Health Canada, and EMA. Signed partnerships from the Gulf to the Maghreb. Not a promise, a track record.
Are You Our Ideal Client?
Pharma & biotech SMEs —
North America or Europe
Products in clinical development or already on the market. You want to enter the MENA market or monetize your IP.
MENA companies seeking innovation
You wish to access Canadian or European biotechnological innovation.
Organizations seeking strategic partners
You need qualified licensees, distributors or co-developers in the Middle East and Africa.
Therapeutic Areas
Oncology
Precision medicine
Medical devices
Neurology
Respiratory
Endocrinology
Biosimilars
Cardiology
Nutritional Supplements
Our 4-Step Process
1
Discovery & Strategy
2
Regulatory Navigation
3
Partnership Development
4
Execution & Growth
Why Act Now?
The MEA market reaches $141 billion by 2034. Over 70% of medicines in the Middle East are imported. Partnership windows open and close faster than most companies realize. The companies that act today are building the positions their competitors will spend years trying to catch up with.